Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Seam, Nitin ^a,b   Suffredini, Anthony F ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; PLACEBO;

CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; MORTALITY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SURVIVAL TIME; TREATMENT DURATION; BLEEDING; CHEMICALLY INDUCED; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; MALE;

ANTITHROMBINS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; SEPSIS;

EID: 84927710934     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0639-1     Document Type: Note

References (16)

1. Iba T, Saitoh D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated coagulation: a secondary survey. Crit Care 2014, 18:497..
2. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823. 10.1378/chest.101.3.816, 1531791.
3. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933. 10.1111/j.1538-7836.2004.00955.x, 15550023.
4. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007, 5:604-606. 10.1111/j.1538-7836.2007.02313.x, 17096704.
5. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, Kim HK, Nielsen JD, Dempfle CE, Levi M, Toh CH, The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis: Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013, 10.1111/jth.12155..
6. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010, 125:6-11. 10.1016/j.thromres.2009.08.017, 19782389.
7. Iba T. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan. J Thromb Haemost 2013, 11:2076-2078. 10.1111/jth.12344, 23819713.
8. Wada H, Thachil J, Di Nisio M, Kurosawa S, Gando S, Toh CH. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. J Thromb Haemost 2013, 11:2078-2079. 10.1111/jth.12366, 23927431.
9. Afshari A, Wetterslev J, Brok J, Moller AM: Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008, CD005370..
10. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133. 10.1016/j.thromres.2012.03.021, 22542365.
11. Minneci PC, Deans KJ, Cui X, Banks SM, Natanson C, Eichacker PQ. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 2006, 34:538-541. 10.1097/01.CCM.0000199035.29165.A7, 16424739.
12. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
13. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97. 10.1111/j.1538-7836.2005.01697.x, 16409457.
14. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002, 30(5 Suppl):S325-S331. 10.1097/00003246-200205001-00024, 12004255.
15. Kellum JA, Uchino S. International differences in the treatment of sepsis: are they justified?. JAMA 2009, 301:2496-2497. 10.1001/jama.2009.850, 19531792.
16. Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014, 12:1010-1019. 10.1111/jth.12596, 24801203.